molmed

Investors

MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 42,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”

MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 42,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility” ▾

Investors

Outcome of ordinary and extraordinary Shareholders’ Meeting

Outcome of ordinary and extraordinary Shareholders’ Meeting ▾

Investors

Ordinary and extraordinary shareholders' meeting November 7 2016

Ordinary and extraordinary shareholders' meeting November 7 2016 ▾

News & Events

Stay update

EBMT Workshop on Relapse after HSCT ▾

EBMT Workshop on Relapse after HSCT

Location: Hamburg, Germany

MolMed at this event: attending

Investors

Notice of ordinary and extraordinary shareholders' meeting November 7 2016

Notice of ordinary and extraordinary shareholders' meeting November 7 2016 ▾

Investors

Resolutions by the Board of Directors of MolMed S.p.A.

Resolutions by the Board of Directors of MolMed S.p.A. ▾

Investors

Interim financial report as of 30 September 2016

Interim financial report as of 30 September 2016 ▾

News & Events

Stay update

Come of age ... Immunotherapy for Multiple Myeloma ▾

Come of age ... Immunotherapy for Multiple Myeloma

Location: Berlin, Germany

MolMed at this event: attending

Investors

Data presented at EBMT symposium support Zalmoxis® innovative therapy potential in addressing life-threatening condition

Data presented at EBMT symposium support Zalmoxis® innovative therapy potential in addressing life-threatening condition ▾

Investors

MolMed future revenues will benefit from a review of the strategic agreement with GlaxoSmithKline

MolMed future revenues will benefit from a review of the strategic agreement with GlaxoSmithKline ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.